[1] Cable JK, Grider MH. Physiology, Progesterone. 2020.
[2] Solano ME, Arck PC. Steroids, pregnancy and fetal development. Frontiers in immunology. 2020;10:3017. https://doi.org/10.3389/fimmu.2019.03017.
[3] Haider R. Anatomy of the Breast. International Journal of Scientific Multidisciplinary Research. 2023;1(5):401-22. https://doi.org/10.55927/ijsmr.v1i5.4394.
[4] Watkins EJ. Overview of breast cancer. Journal of the American Academy of PAs. 2019;32(10):13-7. https://doi.org/10.1097/01.JAA.0000580524.95733.3d.
[5] Weaver M, Stuckey A. Benign breast disorders. Obstetrics and Gynecology Clinics. 2022;49(1):57-72. https://doi.org/10.1016/j.ogc.2021.11.003.
[6] Horwitz KB, Sartorius CA. 90 years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future. Journal of Molecular Endocrinology. 2020;65(1):T49-63. https://doi.org/10.1530/JME-20-0104.
[7] Aggelis V, Johnston SR. Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer. Drugs. 2019;79:1849-66. https://doi.org/10.1007/s40265-019-01208-8.
[8] Lei JT, Gou X, Seker S, Ellis MJ. ESR1 alterations and metastasis in estrogen receptor positive breast cancer. Journal of cancer metastasis and treatment. 2019;5:38. https://doi.org/10.20517/2394-4722.2019.12.
[9] Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation (s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2019;1872(2):188315. https://doi.org/10.1016/j.bbcan.2019.188315.
[10] Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet Oncology. 2019;20(10):1360-9. https://doi.org/10.1016/S1470-2045(19)30420-6.
[11] Allison KH, Hammond ME, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Archives of pathology & laboratory medicine. 2020;144(5):545-63. https://doi.org/10.5858/arpa.2019-0904-SA.
[12] Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nature Communications. 2022;13(1):3127. https://doi.org/10.1038/s41467-022-30898-0.
[13] Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, D. Crawford M, et al. A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences. 2010;107(15):6994-9. https://doi.org/10.1073/pnas.0912708107.
[14] Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer and metastasis reviews. 2009;28:369-78. https://doi.org/10.1007/s10555-009-9188-5.
[15] Azodian Ghajar H, Koohi Ortakand R. The Promising Role of MicroRNAs, Long Non-Coding RNAs and Circular RNAs in Urological Malignancies. Translational Research in Urology. 2022;4(1):9-23. https://doi.org/10.22034/tru.2022.315706.1088.
[16] Dilsiz N. Role of exosomes and exosomal microRNAs in cancer. Future science OA. 2020;6(4):FSO465. https://doi.org/10.2144/fsoa-2019-0116.
[17] Lebron-Zapata L, Jochelson MS. Overview of breast cancer screening and diagnosis. PET clinics. 2018;13(3):301-23. https://doi.org/10.1016/j.cpet.2018.02.001.
[18] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery. 2021;88:105906. https://doi.org/10.1016/j.ijsu.2021.105906.
[19] GRADE Working Group. Grading quality of evidence and strength of recommendations. Bmj. 2004;328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490.
[20] Fu A, Yu Z, Zhang E, Song J. Long noncoding RNA ZBED3‐AS1 restrains breast cancer progression by targeting the microRNA‐513a‐5p/KLF6 axis. Thoracic cancer. 2021;12(20):2719-31. https://doi.org/10.1111/1759-7714.14111.
[21] Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, et al. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis. 2018;39(2):98-108. https://doi.org/10.1093/carcin/bgx126.
[22] Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Molecular and cellular endocrinology. 2012;355(1):15-24. https://doi.org/10.1016/j.mce.2011.12.020.
[23] Lee JH, Lydon JP, Kim CH. Progesterone suppresses the m TOR pathway and promotes generation of induced regulatory T cells with increased stability. European journal of immunology. 2012;42(10):2683-96. https://doi.org/10.1002/eji.201142317.
[24] Brisken C. Reply to Is progesterone a neutral or protective factor for breast cancer?. Nature Reviews Cancer. 2014;14(2):146. https://doi.org/10.1038/nrc3518-c2.
[25] Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, et al. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer research. 2009;69(21):8332-40.
https://doi.org/10.1158/0008-5472.CAN-09-2206.